ERIS Lifescience

Why is ERIS Lifesciences Ltd falling/rising?

As of 24-Aug, ERIS Lifesciences Ltd's stock price is 1,326.20, showing a slight increase today but has underperformed significantly over various timeframes, including a 25.03% decline over the past year. Despite some positive financial indicators, the stock faces challenges due to declining performance metrics and reduced investor engagement.

As of 24-Aug, ERIS Lifesciences Ltd's stock price is currently at 1,326.20, reflecting a slight increase of 0.7 (0.05%). However, the stock has been underperforming in various timeframes, with a 1-week decline of 1.72%, a 1-month drop of 5.20%, and a year-to-date decrease of 11.81%. Over the past year, the stock has fallen by 25.03%, while the benchmark Sensex has only decreased by 4.84% during the same period.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 0.42%. It is also trading below its moving averages across multiple timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, there has been a significant drop in investor participation, with delivery volume on 21 August falling by 41.2% compared to the 5-day average.<BR><BR>Despite these negative indicators, there are some positive factors supporting the stock. The company has demonstrated high management efficiency with a return on capital employed (ROCE) of 15.33% and a strong ability to service its debt, as indicated by a healthy EBIT to interest ratio of 12.66. Furthermore, the company reported positive results in June, including a low debt-equity ratio of 0.60 times and the highest operating profit to interest ratio at 6.35 times.<BR><BR>Overall, while the stock has shown a minor increase today, the broader context of declining performance metrics and reduced investor engagement suggests that the stock is facing challenges that may contribute to its overall downward trend.

Which are the latest news on ERIS Lifescience?

Who are in the management team of ERIS Lifescience?

The management team of ERIS Lifescience includes Amit Indubhushan Bakshi (CMD & Executive Director), Kaushal Kamlesh Shah, Inderjeet Singh Negi, Krishnakumar Vaidyanathan (Executive Director/WTD/Chairman), and four Independent Non-Executive Directors: Sujesh Vasudevan, Prashant Gupta, Rajeev Narotam Dalal, and Kalpana Unadkat. They are responsible for guiding the company's strategic direction and operations.

The management team of ERIS Lifescience includes the following individuals:<BR><BR>1. Amit Indubhushan Bakshi - CMD & Executive Director<BR>2. Kaushal Kamlesh Shah - WTD & Executive Director<BR>3. Inderjeet Singh Negi - WTD & Executive Director<BR>4. Krishnakumar Vaidyanathan - Executive Director / WTD / Chairman<BR>5. Sujesh Vasudevan - Independent Non-Executive Director<BR>6. Prashant Gupta - Independent Non-Executive Director<BR>7. Rajeev Narotam Dalal - Independent Non-Executive Director<BR>8. Kalpana Unadkat - Independent Non-Executive Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

What does ERIS Lifescience do?

Eris Lifesciences Ltd manufactures and markets pharmaceutical products, classified as a Small Cap company with a market cap of INR 18,723 Cr. As of June 2026, it reported net sales of 873 Cr and a net profit of 142 Cr.

Overview: <BR>Eris Lifesciences Ltd is engaged in the manufacturing and marketing of pharmaceutical products and operates within the Pharmaceuticals & Biotechnology industry, classified as a Small Cap company.<BR><BR>History: <BR>Eris Lifesciences Limited was incorporated on January 25, 2007, and changed its name to 'Eris Lifesciences Private Limited' on February 9, 2007. The company was converted into a Public Limited Company and renamed 'Eris Lifesciences Limited' on February 2, 2017. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>- Net Sales: 873 Cr (Quarterly Results - Jun 2026) <BR>- Net Profit: 142 Cr (Quarterly Results - Jun 2026) <BR>- Market Cap: INR 18,723 Cr (Small Cap) <BR><BR>Key Metrics: <BR>- P/E: 29.00 <BR>- Industry P/E: 37 <BR>- Dividend Yield: 0.54% <BR>- Debt Equity: 0.59 <BR>- Return on Equity: 16.20% <BR>- Price to Book: 4.77 <BR><BR>Contact Details: <BR>Address: 8th Floor Commerce House -IV, Prahladnagar 100 FT Road Ahmedabad Gujarat : 380015 <BR>Tel: 91-79-30451000 <BR>Email: complianceofficer@erislifesciences. <BR>Website: http://www.eris.co.in

Who are the peers of the ERIS Lifescience?

ERIS Lifescience's peers include Acutaas Chemical, Pfizer, Granules India, Astrazeneca Pharma, Caplin Point Lab, OneSource Specialty, Cohance Life, Natco Pharma, Alivus Life, and Alembic Pharma. In terms of management risk, growth, and capital structure, ERIS Lifescience ranks well but has a 1-year return of -17.64%, better than Cohance Life's -54.93% but significantly lower than Acutaas Chemical's 136.06%.

Peers: The peers of ERIS Lifescience are Acutaas Chemical, Pfizer, Granules India, Astrazeneca Phar, Caplin Point Lab, OneSource Speci., Cohance Life, Natco Pharma, Alivus Life, and Alembic Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Astrazeneca Phar, while Good management risk is found at Acutaas Chemical, Pfizer, Granules India, Caplin Point Lab, ERIS Lifescience, Natco Pharma, and Alivus Life, and the rest. Below Average management risk is noted at OneSource Speci., while Average management risk is found at Cohance Life. Growth is Excellent for Acutaas Chemical and the rest, while Below Average growth is seen at Pfizer, Granules India, Caplin Point Lab, ERIS Lifescience, Natco Pharma, and Alivus Life. Average growth is noted at Astrazeneca Phar, and Below Average growth is found at OneSource Speci., Cohance Life, and Alembic Pharma. Capital Structure is Excellent for Acutaas Chemical, Pfizer, Granules India, Astrazeneca Phar, Caplin Point Lab, Natco Pharma, and Alivus Life, while Good capital structure is observed at ERIS Lifescience, and Below Average capital structure is noted at OneSource Speci.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Acutaas Chemical at 136.06%, while the peer with the lowest is Cohance Life at -54.93%. ERIS Lifescience's 1-year return is -17.64%, which is significantly lower than Acutaas Chemical's return and higher than Cohance Life's. Additionally, Cohance Life and ERIS Lifescience are the only peers with negative six-month returns.

How big is ERIS Lifescience?

As of 14th August, ERIS Lifesciences Ltd has a market capitalization of 18,832.78 Cr, with recent net sales of 3,229.67 Cr and net profit of 643.91 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: ERIS Lifesciences Ltd has a market capitalization of 18,832.78 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 3,229.67 Cr, while the sum of Net Profit for the same period is 643.91 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 2,854.36 Cr, and Total Assets amount to 6,744.13 Cr.

Are ERIS Lifesciences Ltd latest results good or bad?

ERIS Lifesciences Ltd's latest results show strong revenue growth with a net profit increase of 20.68% and record net sales of ₹873.25 crores. However, operating margins have declined due to rising costs, indicating potential concerns about profitability and cost management.

ERIS Lifesciences Ltd's latest results present a mixed picture. On the positive side, the company reported a net profit of ₹142.39 crores for Q1 FY27, which is a significant increase of 20.68% year-on-year. Additionally, net sales reached an all-time high of ₹873.25 crores, reflecting a year-on-year growth of 12.97%. This strong revenue performance indicates robust demand, particularly in their chronic therapy portfolio, which includes cardiovascular and anti-diabetic segments.<BR><BR>However, there are notable concerns regarding margin compression. The operating margin decreased to 34.09%, down from 35.86% in the same quarter last year, primarily due to rising employee costs and operational expenses. This decline in margin suggests that while sales are growing, the company's profitability is under pressure.<BR><BR>Overall, while the revenue growth is commendable and reflects the company's strong market position, the margin erosion raises questions about its cost management and operational efficiency. Investors may need to weigh these factors carefully when assessing the company's performance.

Should I buy, sell or hold ERIS Lifesciences Ltd?

Has ERIS Lifesciences Ltd declared dividend?

Yes, ERIS Lifesciences Ltd has declared a dividend of 721%, amounting to ₹7.35 per share, with an ex-date of February 13, 2025. While recent total returns have varied, the company has shown strong growth over the longer term, particularly in the 2 to 5-year periods.

ERIS Lifesciences Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 721%<BR>- Amount per share: 7.35<BR>- Ex-date: Feb-13-2025<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 0.17%, the dividend return was 0.53%, resulting in a total return of 0.7%.<BR><BR>Over the 6-month period, the price return decreased by 19.21%, while the dividend return contributed 0.44%, leading to a total return of -18.77%.<BR><BR>For the 1-year period, the price return was down by 11.53%, with a dividend return of 0.46%, culminating in a total return of -11.07%.<BR><BR>In the 2-year period, the price return increased by 48.03%, and the dividend return was 1.59%, resulting in a total return of 49.62%.<BR><BR>During the 3-year period, the price return rose by 119.67%, with a dividend return of 2.24%, leading to a total return of 121.91%.<BR><BR>For the 4-year period, the price return was up by 87.01%, while the dividend return contributed 3.36%, resulting in a total return of 90.37%.<BR><BR>In the 5-year period, the price return increased by 89.77%, with a dividend return of 3.96%, leading to a total return of 93.73%.<BR><BR>Overall, ERIS Lifesciences Ltd has declared a significant dividend, and while recent total returns show variability, the longer-term performance indicates strong growth, particularly over the 2 to 5-year periods.

When is the next results date for ERIS Lifesciences Ltd?

The next results date for ERIS Lifesciences Ltd is 13 February 2026.

The next results date for ERIS Lifesciences Ltd is scheduled for 13 February 2026.

Is ERIS Lifescience technically bullish or bearish?

As of December 1, 2025, ERIS Lifescience's technical trend is neutral with mixed signals, showing a sideways movement influenced by mildly bearish MACD and KST indicators, while moving averages suggest a slight bullish stance on the daily chart.

As of 1 December 2025, the technical trend for ERIS Lifescience has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD is mildly bearish on both weekly and monthly time frames, while the Bollinger Bands show a bearish signal weekly but mildly bullish monthly. The moving averages indicate a mildly bullish stance on the daily chart, contrasting with the bearish signals from the KST on both weekly and monthly time frames. The Dow Theory suggests a mildly bullish trend on the weekly chart, but there is no clear trend on the monthly. Overall, the lack of strong bullish or bearish signals and the sideways trend indicate a neutral stance with no clear strength in either direction.

How has been the historical performance of ERIS Lifescience?

ERIS Lifescience has shown significant growth, with net sales increasing from 1,074.06 Cr in March 2020 to 2,893.64 Cr in March 2025, and operating profit rising from 376.60 Cr to 1,035.56 Cr. However, profit after tax fluctuated, peaking at 406.11 Cr in March 2022 and declining to 351.84 Cr by March 2025.

Answer:<BR>The historical performance of ERIS Lifescience shows significant growth in net sales and operating profit over the years, with net sales reaching 2,893.64 Cr in March 2025, up from 1,074.06 Cr in March 2020. The operating profit (PBDIT) also increased to 1,035.56 Cr in March 2025 from 376.60 Cr in March 2019. However, profit after tax saw fluctuations, peaking at 406.11 Cr in March 2022 before declining to 351.84 Cr in March 2025. The company's total assets grew from 1,381.39 Cr in March 2020 to 6,744.13 Cr in March 2025, while total liabilities increased from 1,381.39 Cr to 6,744.13 Cr in the same period. Cash flow from operating activities improved significantly, reaching 1,065.00 Cr in March 2025 compared to 271.00 Cr in March 2020.<BR><BR>Breakdown:<BR>ERIS Lifescience has demonstrated a robust upward trend in its financial performance, particularly in net sales, which surged from 1,074.06 Cr in March 2020 to 2,893.64 Cr in March 2025. This growth in revenue is accompanied by a notable increase in operating profit, which rose from 376.60 Cr to 1,035.56 Cr over the same period. Despite this positive trend, profit after tax experienced some volatility, peaking at 406.11 Cr in March 2022 before settling at 351.84 Cr in March 2025. The company's total assets expanded significantly, reflecting its growth strategy, climbing from 1,381.39 Cr to 6,744.13 Cr. Total liabilities mirrored this growth, also increasing to 6,744.13 Cr. Cash flow from operating activities saw a remarkable improvement, indicating enhanced operational efficiency, with figures rising from 271.00 Cr in March 2020 to 1,065.00 Cr in March 2025.

Is ERIS Lifescience overvalued or undervalued?

As of September 5, 2025, ERIS Lifescience is considered overvalued with a valuation grade of "expensive," reflected in its high PE ratio of 60.82 and EV to EBITDA ratio of 24.71, especially when compared to peers like Sun Pharma and Cipla, despite a year-to-date return of 26.09% that underperformed against the Sensex's 3.29%.

As of 5 September 2025, the valuation grade for ERIS Lifescience has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 60.82, an EV to EBITDA ratio of 24.71, and a PEG ratio of 37.14, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Sun Pharma has a PE ratio of 33.33 and an EV to EBITDA of 22.53, while Cipla is more attractively valued with a PE of 23.25 and an EV to EBITDA of 16.37. The high valuation metrics of ERIS Lifescience suggest that it is trading at a premium compared to its peers, which reinforces the conclusion of being overvalued. Notably, despite recent stock performance showing a 26.09% return year-to-date, it has underperformed against the Sensex's 3.29% return during the same period.

Who are the top shareholders of the ERIS Lifescience?

The top shareholders of ERIS Lifescience include promoter Amit Indubhusan Bakshi with 42.84%, mutual funds holding 16.59%, foreign institutional investors at 8.43%, and the highest public shareholder, Lilac Investments Limited, with 8.79%. Individual investors collectively own 9.16% of the shares.

The top shareholders of ERIS Lifescience include the promoters, who hold a significant majority of the shares. The promoter with the highest holding is Amit Indubhusan Bakshi, owning 42.84% of the company. Additionally, mutual funds hold 16.59% of the shares, represented by 22 schemes, while foreign institutional investors (FIIs) account for 8.43% through 135 different entities. The highest public shareholder is Lilac Investments Limited, which holds 8.79%. Individual investors collectively own 9.16% of the shares.